HC Wainwright Reiterates “Neutral” Rating for Sutro Biopharma (NASDAQ:STRO)

Sutro Biopharma (NASDAQ:STRO)‘s stock had its “neutral” rating restated by research analysts at HC Wainwright in a note issued to investors on Monday, Marketbeat Ratings reports. They currently have a $2.00 target price on the stock, down from their prior target price of $12.00. HC Wainwright’s target price indicates a potential upside of 123.19% from the stock’s previous close.

Several other research firms have also commented on STRO. Wells Fargo & Company dropped their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Wednesday, December 11th. Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $8.00 to $2.00 in a report on Friday, March 14th. Bank of America lowered Sutro Biopharma from a “buy” rating to an “underperform” rating and dropped their target price for the stock from $11.00 to $1.00 in a report on Friday, March 14th. Finally, Citizens Jmp lowered Sutro Biopharma from an “outperform” rating to a “market perform” rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Sutro Biopharma presently has an average rating of “Hold” and an average target price of $6.63.

Sutro Biopharma Stock Down 3.9 %

Shares of NASDAQ:STRO opened at $0.90 on Monday. Sutro Biopharma has a 52-week low of $0.76 and a 52-week high of $6.13. The stock has a market cap of $73.89 million, a price-to-earnings ratio of -0.56 and a beta of 1.22. The business has a 50-day moving average price of $1.71 and a 200-day moving average price of $2.67.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($2.10). Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The firm had revenue of $14.00 million during the quarter, compared to analysts’ expectations of $10.44 million. During the same quarter in the previous year, the business earned ($1.78) earnings per share. As a group, equities analysts anticipate that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Institutional Trading of Sutro Biopharma

Several institutional investors have recently bought and sold shares of STRO. Dynamic Technology Lab Private Ltd acquired a new stake in Sutro Biopharma in the fourth quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Sutro Biopharma in the fourth quarter worth approximately $32,000. Vontobel Holding Ltd. boosted its stake in shares of Sutro Biopharma by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after acquiring an additional 10,000 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Sutro Biopharma by 74.3% in the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company’s stock worth $50,000 after acquiring an additional 11,494 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Sutro Biopharma in the fourth quarter worth approximately $55,000. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.